1,25-Dihydroxyvitamin D3 increases testosterone-induced 17beta-estradiol secretion and reverses testosterone-reduced connexin 43 in rat granulosa cells

Ching-Tien Lee¹, Jiz-Yuh Wang², Kuang-Yi Chou³ and Ming-I Hsu⁴*

Abstract

Background: Aromatase converts testosterone into 17beta-estradiol in granulosa cells, and the converted 17beta-estradiol contributes to follicular maturation. Additionally, excessive testosterone inhibits aromatase activity, which can lead to concerns regarding polycystic ovary syndrome (PCOS). Generally, 1,25-dihydroxyvitamin D3 (1,25D3) supplements help to improve the symptoms of PCOS patients who exhibit low blood levels of 1,25D3. Therefore, this study investigated the interaction effects of 1,25D3 and testosterone on estrogenesis and intercellular connections in rat granulosa cells.

Methods: Primary cultures of granulosa cells were treated with testosterone or testosterone plus 1,25D3, or pre-treated with a calcium channel blocker or calcium chelator. Cell lysates were subjected to western blot analysis to determine protein and phosphorylation levels, and 17beta-estradiol secretion was examined using a radioimmunoassay technique. Cell viability was evaluated by MTT reduction assay. Connexin 43 (Cx43) mRNA and protein expression levels were assessed by qRT-PCR, western blot, and immunocytochemistry.

Results: Testosterone treatment (0.1 and 1 microg/mL) increased aromatase expression and 17beta-estradiol secretion, and the addition of 1,25D3 attenuated testosterone (1 microg/mL)-induced aromatase expression but improved testosterone-induced 17beta-estradiol secretion. Furthermore, testosterone-induced aromatase phosphotyrosine levels increased at 10 min, 30 min and 1 h, whereas 1,25D3 increased the longevity of the testosterone effect to 6 h and 24 h. Within 18–24 h of treatment, 1,25D3 markedly enhanced testosterone-induced 17beta-estradiol secretion. Additionally, pre-treatment with a calcium channel blocker nifedipine or an intracellular calcium chelator BAPTA-AM reduced 1,25D3 and testosterone-induced 17beta-estradiol secretion. Groups that underwent testosterone treatment exhibited significantly increased estradiol receptor beta expression levels, which were not affected by 1,25D3. Neither testosterone nor 1,25D3 altered 1,25D3 receptor expression. Finally, at high doses of testosterone, Cx43 protein expression was decreased in granulosa cells, and this effect was reversed by co-treatment with 1,25D3.

Conclusions: These data suggest that 1,25D3 potentially increases testosterone-induced 17beta-estradiol secretion by regulating aromatase phosphotyrosine levels, and calcium increase is involved in both 1,25D3 and testosterone-induced 17beta-estradiol secretion. 1,25D3 reverses the inhibitory effect of testosterone on Cx43 expression in granulosa cells.

Keywords: 17beta-estradiol, Estrogenesis, Connexin 43, Testosterone, 1,25-dihydroxyvitamin D3, Polycystic ovary syndrome, Calcium, Granulosa cells

* Correspondence: hsumingi@yahoo.com.tw

²Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

Full list of author information is available at the end of the article

© 2014 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Biosynthesis of 17β-estradiol from androgen precursors is catalysed by the enzyme aromatase, which is expressed from the cyp19 gene and exists in the ovaries, placenta, testes, breasts, brain, fat, liver and muscles [1]. 17β-Estradiol production and follicular development are controlled by the expression level and activity of aromatase [2]. During follicular growth, aromatase mRNA expression levels in granulosa cells from dominant follicles and 17β-estradiol levels in the follicular fluid are significantly increased [3,4].

Various studies have demonstrated the role of androgens in stimulating follicular development. Androgen receptors (AR) are observed in primary follicles and advanced-stage follicles, and are detected in the granulosa cells of primordial follicles [5]. Androgens have been shown to stimulate the growth of small antral follicles and inhibit apoptosis of preovulatory follicles in primate ovaries [6,7], whereas AR-knockout mice exhibit greatly increased apoptosis of granulosa cells in preovulatory follicles [8]. Testosterone and dihydrotestosterone (DHT) stimulate the growth of cultured follicles, increase the number of follicles and increase granulosa cell proliferation in mammalian cells [6,7]. Testosterone and androstenedione significantly increase the abundance of aromatase mRNA and the accumulation of 17β-estradiol [2,9,10]. However, excessive testosterone is involved in polycystic ovary syndrome (PCOS), which is the most common endocrine disorder in females and is associated with arrested follicular development and the failure to select a dominant follicle [11]. Deficiency of 1,25-dihydroxyvitamin D$_3$ (1,25D$_3$), an active form of vitamin D, is a common risk factor in patients with PCOS [12,13]. A daily 1,25D$_3$ supplement enhances the intestinal absorption of calcium and alleviates both PCOS symptoms and gonadal dysfunction in 1,25D$_3$ receptor (VDR)-null mutant mice [14].

1,25D$_3$ plays important roles in calcium homeostasis, bone metabolism, and cell differentiation, proliferation, and apoptosis. Immunohistochemistry assays have demonstrated that VDR localizes to the follicles and predominantly exists in the nuclei of granulosa cells, suggesting that it has some role in reproduction [15]. Recent studies have demonstrated that aromatase activity and expression level are low in the ovaries of VDR-null mutant mice, but the activity is increased to 60% of wild-type levels by calcium supplementation in the normal range. Circulating 17β-estradiol levels are also low in VDR-null mutant mice and do not rise after calcium supplementation [16]. Taken together, these results indicate that 1,25D$_3$ plays a role in estrogenesis that is only partially mediated by extracellular calcium homeostasis.

It has recently been shown that signalling via 1,25D$_3$/VDR-mediated protein tyrosine phosphorylation occurs in bone, intestine, muscle and cancer cells [17]. The fast nongenomic responses of 1,25D$_3$/VDR in muscle cells involve the phosphotyrosine form of a downstream protein, c-Src [18,19]. Interestingly, c-Src is also downstream of the estradiol/membrane-associated estradiol receptor (ER) in the stimulation of aromatase activity. The phosphorylation of aromatase at tyrosine 361 is crucial in the up-regulation of aromatase activity through the estradiol/membrane-associated ER and c-Src signalling in mammalian cell lines [20]. The AR is also localized in the plasma membrane and is associated with Src after testosterone treatment in Sertoli cells [21].

A gap junction is a type of intercellular connection that enables the transfer of various small molecules and ions between cells. Such transfers between granulosa cells and oocytes have been implicated in playing important roles in follicular development and oocyte growth [22]. Gap junctions between granulosa cells contain abundant levels of connexin (Cx) 43, which is present at every stage of follicular growth [23]. The level of Cx43 protein expression increases during follicular development and decreases with follicular atresia [24]. Oocytes from Cx43-null mice failed to reach meiotic maturation, resulting in infertility [24]. Wu et al. demonstrated that excess DHT reduces Cx43 expression and impairs communication between granulosa cells [25]. Additionally, 1,25D$_3$ increases Cx43 protein levels and Cx43 mRNA stability via the nuclear VDR in human skin fibroblasts [26].

However, no studies have investigated the effect of the testosterone and 1,25D$_3$ interaction on aromatase expression and phosphorylation in granulosa cells. Additionally, the effects of 1,25D$_3$ and testosterone-regulated 17β-estradiol production and intercellular communication in granulosa cells have not been fully elucidated. We therefore investigated the interactions of 1,25D$_3$ and testosterone to clarify their effects on aromatase protein expression and tyrosine phosphorylation, 17β-estradiol secretion and Cx43 protein expression in cultured ovarian granulosa cells.

Methods

Animal preparation

Immature female Sprague–Dawley rats were housed in plastic cages and maintained on a 12 h light/12 h dark cycle (light on at 6:00 a.m.) with food and water available continuously. The experimental procedures were consistent with the Guidelines of Animal Use and Care from the National Institute of Health and were approved by the Institutional Animal Care and Use Committee of Taipei Medical University-Wang Fang Hospital, Taiwan. Immature female rats at 23–24 days of age were injected with 15 IU PMSG (Sigma, St. Louis, MO, USA) for 48 h to stimulate the development of preantral follicles to antral
follicles, and the ovaries of the animals were removed after the animals were sacrificed.

**Granulosa cell culture**

The ovaries were cleared from the surrounding fat and oviduct, and punctured with 27-gauge needles in phenol red-free Dulbecco’s Modified Eagle’s medium (DMEM)/F12 medium (Invitrogen, Carlsbad, CA, USA), modified as described previously [27]. Granulosa cells were pelleted by centrifugation at 1000 rpm (4°C, 10 min) and resuspended in phenol red-free DMEM/F12 medium with 0.1% fatty acid-free bovine serum albumin, 1% fetal bovine serum, and 2 μg/mL bovine insulin. The follicular debris was then removed, and the granulosa cell suspensions were filtered through a cell strainer (BD Falcon, Bedford, MA, USA). The cells were plated at a concentration of 2.5 × 10⁶ per well in a 6-well plate and were allowed to attach and grow to confluence for 1 day at 37°C, 5% CO₂, and 95% air. The cultured cells were then incubated in serum/phenol red-free medium (DMEM/F12 containing 0.1% lactalbumin enzymatic hydrolysate) overnight before the beginning of treatment. The cells were treated with different doses of testosterone (0.01, 0.1 or 1 μg/mL) or testosterone combined with 1,25D₃ (0.1 μM) in 2 mL of serum/phenol red-free medium for 24 h. Granulosa cells were pretreated with an L-type calcium channel blocker nifedipine (NIF, 10 μM, Sigma, St. Louis, MO, USA) or an intracellular calcium chelator bis-(a-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid, tetra(acetoxyethyl)-ester (BAPTA-AM, 10 μM, Tocris, Minneapolis, MN, USA) for 30 min, pretreated with 1,25D₃ for 15 min, and treated with one of three testosterone doses or vehicle for 24 h. At the end of the incubation period, the medium was collected, and the cells were lysed in ice-cold lysis buffer containing 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% Triton X-100, protease inhibitors and phosphatase inhibitors. A protein extract was used as a blocking buffer to minimize the background caused by protein G contamination, and an EasyBlot anti-mouse IgG (HRP) was used that specifically reacts with the native form of mouse IgG and does not bind to the denatured form.

**Western blot**

The protein content of the extracts was determined using the Bio-Rad Protein Assay Reagent. Equal amounts of the protein extract (15 μg) were mixed with loading buffer and subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by transfer to a PVDF (polyvinylidene difluoride) membrane (Millipore, Billerica, MA, USA). After blocking for 1 h with 5% non-fat milk powder at room temperature for 1 h. For experiments involving re-immunoblotting to different antibodies, the blots were stripped in 0.2 M glycine (pH 2.5) and 0.05% Tween-20 at 80°C for 20 min and then rinsed twice with 0.09 M boric acid (pH 7.4), 0.9% NaCl, and 0.05% Tween-20. The membranes were immunoblotted with different antibodies: aromatase (1:1000, Serotec, Kidlington, Oxford, UK), phosphotyrosine (1:5000, Millipore, Billerica, MA, USA), Cx43 (1:1000, Novex, San Diego, CA, USA), estradiol receptor β (ERβ) (1:1000, GeneTex, San Antonio, Texas, USA), VDR (1:1000, GeneTex, San Antonio, Texas, USA), and β-actin (1:10000, Chemicon, Temecula, CA, USA). Immunoreactivity was detected by chemiluminescence autoradiography (ECL kit, Millipore, Billerica, MA, USA) in accordance with the manufacturer's instructions. The protein bands were quantified using the NIH image J Software.

**Aromatase activity assay**

The enzyme aromatase is responsible for the synthesis of estradiol from testosterone. Hence, the effect of 1,25D₃ on 17β-estradiol secretion by granulosa cells was used as an indicator of aromatase activity (modified by Zaher Merhi et al., 2014) [28]. To study the effect of 1,25D₃ on the aromatase activity, granulosa cells were cultured in 24-well culture plates for 24 h to attach to the plate. After 24 h of culture, the cells were treated with testosterone or 1,25D₃/testosterone (i.e. 1,25D₃ plus testosterone), the medium was collected at the indicated times (10 min, 30 min, 1 h, 6 h and 24 h), and the 17β-estradiol level was measured. In order to exclude the earlier difference in 17β-estradiol secretion, the culture medium was removed after 18 h and replaced with fresh
medium supplemented with testosterone or 1,25D₃/testosterone for another 6 h (18–24 h) treatment. The medium was collected for the measurement of 17β-estradiol concentrations at 18–24 h after the addition of the testosterone or 1,25D₃/testosterone.

Radioimmunoassay
The cell culture medium was collected and stored at −80°C until the assay was performed. 17β-Estradiol levels were assayed using a Coat-A-Count Estradiol RIA kit (Siemens, Dublin, Ireland) according to the manufacturer's protocol. 1 mL of 125I-labeled estradiol and 100 μL samples were incubated in anti-estradiol antibody-coated tubes for 3 h at room temperature. After decanting the mixture and washing the tubes, the radioactivity levels of the tubes were counted in a gamma counter. The counts are inversely related to the amount of 17β-estradiol present in the sample. The intra assay coefficients of variation for assays ranged between 3% and 16%, with a mean of 10.2%. The percentage cross-reactivity of this antiserum was 17α-estradiol: not detectable; estriol: 0.32%; estrone-β-D-glucuronide: 1.8%. The limit and highest of detection of the assay was 0–3600 pg/mL.

3-(4,5-dimethylthianol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay
Cell viability was measured by a colorimetric MTT reduction assay performed as first described by Mosoman [29]. Each culture well was incubated in 0.5 mg/mL MTT (Sigma, St. Louis, MO, USA) culture medium followed by incubation for 4 h in 5% CO₂ at 37°C. The culture medium was then aspirated, and cells were lysed with DMSO. Quantitation of MTT reduction was assayed by measuring the absorbance at 570 nm (against the 630 nm reference) using an ELISA reader (BioTek, Winooski, VT, USA).

RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total cellular RNA from granulosa cell cultures was isolated using a Total RNA Purification Kit (GeneMark, GMbiolab, Taichung, Taiwan) according to the manufacturer's instructions. RNA concentrations and purity were determined using a NanoDrop ND2000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). First-strand cDNA was synthesized from 300 ng of total RNA using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). The cDNA were used as templates in subsequent qPCR by an ABI 7500 PCR Detection System (Applied Biosystem, Foster City, CA, USA). The primer sequences for Cx43 used for PCR amplifications were as follows: 5′-TTG TTT CTG TCA CCA GTA AC-3′ (antisense) and 5′-GAT GAG GAA GGA AGA GAA GC-3′ (sense). GAPDH was used as the internal control: 5′-CCG CCT GCT TCA CCA CCT TCT-3′ (antisense) and 5′-GTC ATC ATC TCC GCC CCT TCC-3′ (sense). Each reaction contained the RT mixture, primers and SYBR Green Master Mix (Invitrogen, Carlsbad, CA, USA) and was carried out with the following profile: initial heating to 95°C for 10 min followed by 40 cycles of heating to 95°C for 15 s, incubation at 55°C for 30 s and incubation at 72°C for 90 s. Melting-curve analysis and PCR products were run on agarose gels with ethidium bromide staining. Cx43 mRNA levels were normalized to GAPDH and expressed as values relative to the control using the comparative threshold cycle method.

Immunocytochemistry
Granulosa cells were cultured on poly-L-lysine coated coverslips in 6-well plates. After 24 h of treatment, the granulosa cells were fixed in cold 4% paraformaldehyde for 20 min, rinsed three times with phosphate-buffered saline, and permeabilized with 0.1% Triton. Cells were blocked for 1 h with 5% goat serum and incubated for overnight at 4°C with rabbit anti-Cx43 (diluted 1:100, Novex, San Diego, CA, USA). The cells were then incubated for 1 h with FITC-conjugated goat anti-mouse IgG. Nuclei were stained with DAPI. Immunofluorescence images were captured using a confocal microscope (Zeiss LSM 700, Germany).

Statistical analysis
All biochemical data were analyzed with Student’s t-test or a one-way analysis of variance (one-way ANOVA). Specific comparisons between any experimental group and a common control group were made using Dunnett’s t-test. Comparisons between two experimental groups were made using the Student-Newman-Keuls method. Statistical significance was evaluated at the levels of p < 0.05, p < 0.005, and p < 0.001.

Results
1,25D₃ attenuated testosterone-induced aromatase expression and increased 17β-estradiol secretion
To examine whether 1,25D₃ and testosterone regulate aromatase expression and 17β-estradiol secretion in granulosa cells, we treated cells with 0.1 or 1 μg/mL testosterone or 0.1 μM 1,25D₃ plus 1 μg/mL testosterone for 24 h. Western blot analysis revealed that both doses of testosterone increased the aromatase levels (p < 0.005; Figure 1A) compared to vehicle-treated cells, and addition of 0.1 μM 1,25D₃ resulted in a significant decrease of the 1 μg/mL testosterone-induced aromatase levels (p < 0.005; Figure 1A). Additionally, treatment with 1,25D₃ alone attenuated aromatase expression compared to vehicle treatment (p < 0.05; Figure 1A). We also examined 17β-estradiol secretion using a radio-immunoassay and found that both testosterone-treated
groups clearly experienced enhanced 17β-estradiol secretion ($p < 0.005$; Figure 1B). The 1,25D$_3$/testosterone group exhibited significantly increased 17β-estradiol secretion relative to the group without 1,25D$_3$ treatment ($p < 0.005$). Treatment of cells with 0.1 μM 1,25D$_3$ alone for 24 h did not result in a significant increase in 17β-estradiol secretion ($p > 0.05$; Figure 1C). These results indicate that 1,25D$_3$ has the potential to improve testosterone-induced 17β-estradiol secretion but causes a decrease in testosterone-induced aromatase expression.

1,25D$_3$ significantly increased aromatase tyrosine phosphorylation

We evaluated whether the phosphorylation of aromatase was regulated by testosterone and 1,25D$_3$ using immunoprecipitation-western blot analysis. We determined that the 1,25D$_3$/testosterone group exhibited significantly increased the level of aromatase tyrosine phosphorylation at 24 h relative to the testosterone group ($p < 0.05$; Figure 2A, left), and 1,25D$_3$ alone also significantly increased the level of aromatase tyrosine phosphorylation relative to the control group ($p < 0.05$; Figure 2A, right). The left panel in Figure 2B is a positive control that was both immunoprecipitated and immunoblotted with an anti-aromatase antibody, and the right panel is a negative control for IgG. The lysate of the granulosa cells treated with 1,25D$_3$/testosterone showed a significant band attributed to immunoprecipitated aromatase phosphorylase and a weak band for IgG.

We next investigated the time course of the phosphorylation response to testosterone and to 1,25D$_3$/testosterone. Our data demonstrate that testosterone treatment induced aromatase tyrosine phosphorylation at 10 min, 30 min and 1 h, whereas 1,25D$_3$ improved the effect of testosterone at 30 min and increased the duration of the effect to 6 h ($p < 0.05$; Figure 2C) and 24 h (Figure 2A). We also collected the medium for the 17β-estradiol assay and determined that testosterone-induced 17β-estradiol secretion increased at 30 min, 1 h ($p < 0.05$) and 6 h ($n = 5$; $p < 0.001$; Figure 2D). There was no difference in 17β-estradiol secretion between the testosterone-treated groups and the 1,25D$_3$/testosterone-treated groups at up to 6 h ($p > 0.05$; Figure 2D). We also collected the medium 18–24 h after drug treatment and found that the 1,25D$_3$/testosterone-treated group significantly increased 17β-estradiol secretion ($p < 0.05$; Figure 2E). These studies demonstrated that 1,25D$_3$ increased aromatase tyrosine phosphorylation and 17β-estradiol secretion.
Figure 2 (See legend on next page.)
One possible mechanism for 1,25D$_3$/testosterone modulation of 17β-estradiol production is through increasing calcium concentrations. We studied whether NIF or BAPTA-AM could inhibit 1,25D$_3$/testosterone-regulated 17β-estradiol secretion. A radioimmunoassay of 17β-estradiol production is presented in Figure 3. Statistical analysis revealed that testosterone doses (0.01, 0.1 and 1 µg/mL) increased 17β-estradiol production (p < 0.001 and p < 0.005), and 1,25D$_3$ (0.1 µM) increased high-dose (1 µg/mL) testosterone-induced 17β-estradiol secretion (p < 0.05; Figure 3A). Our data demonstrate that pretreatment with NIF reduced 1,25D$_3$ and testosterone-induced 17β-estradiol production is presented in Figure 3. Statistical analysis revealed that testosterone doses (0.01, 0.1 and 1 µg/mL) increased 17β-estradiol production (p < 0.001 and p < 0.005), and 1,25D$_3$ (0.1 µM) increased high-dose (1 µg/mL) testosterone-induced 17β-estradiol secretion (p < 0.05; Figure 3A). Our data demonstrate that pretreatment with NIF reduced 1,25D$_3$ and testosterone-induced 17β-estradiol secretion was mediated by calcium accumulation. (A) Granulosa cells were divided into vehicle, testosterone, testosterone plus 1,25D$_3$ or 1,25D$_3$ alone for 24 h (n = 4–5 in each group). The individual levels of 17β-estradiol were also assayed using a radioimmunoassay. (B) Testosterone-induced 17β-estradiol released by granulosa cells cultured with or without NIF or BAPTA-AM in the absence of 1,25D$_3$ was measured (n = 9 in each group). (C) After NIF or BAPTA-AM treatment for 24 h, cells were subjected to the MTT reduction assay to measure cell viability. MTT reduction data are expressed as the percentage of values relative to the control group. The measurements were performed in triplicate, and each cytotoxicity experiment was repeated four times. The values represent the means ± SEM. #, p < 0.05; ##, p < 0.005 for comparison of two drug groups; a, p < 0.001 for comparison of 0.1 µg/mL and 0.01 µg/mL testosterone; b, p < 0.05 for comparison of 1 µg/mL and 0.1 µg/mL testosterone. The values listed within column indicate the means.
(0.01 and 1 μg/mL)-enhanced 17β-estradiol secretion in granulosa cells (p < 0.05; Figure 3A) but not testosterone (1 μg/mL)-induced 17β-estradiol secretion (Figure 3B). BAPTA-AM reduced 17β-estradiol secretion induced by 1,25D₃/testosterone (0.01, 0.1 and 1 μg/mL) (p < 0.001; Figure 3A) and by testosterone (1 μg/mL) alone (p < 0.05; Figure 3B). We also monitored cell viability using an MTT reduction assay. The viability of cultured cells exposed to NIF (10 μM) or BAPTA-AM (10 μM) did not significantly differ from the control group (p > 0.05; Figure 3C).

Thus, these data revealed that chelation of intercellular calcium with BAPTA-AM resulted in suppression of both testosterone- and 1,25D₃/testosterone-modulated 17β-estradiol secretion, while calcium from the L-type calcium channel was involved in only 1,25D₃/testosterone-modulated 17β-estradiol secretion in cultured granulosa cells.

The effects of testosterone and 1,25D₃ on ERβ or VDR expression

We examined the expression levels of ERβ and VDR in granulosa cells to determine if they were altered by testosterone and 1,25D₃. Western blot analysis revealed that granulosa cells treated with testosterone (0.1 and 1 μg/mL) exhibited markedly increased ERβ expression levels (p < 0.005; Figure 4A) and that 1 μg/mL testosterone treatment increased ERβ expression more than treatment with 0.1 μg/mL testosterone (p < 0.05). However, the two doses of testosterone did not alter VDR levels (p > 0.05; Figure 4B). Additionally, pre-treatment with 1,25D₃ did not alter testosterone-induced ERβ expression and did not influence VDR expression (n = 3–4, p > 0.05; Figure 4A, B). Thus, testosterone alone affected ERβ expression, but 1,25D₃ pre-treatment had no influence on ERβ or VDR in cultured granulosa cells.

1,25D₃ reversed testosterone-induced down-regulation of Cx43 in granulosa cells

Finally, to examine whether 1,25D₃ can affect the testosterone-induced down-regulation of Cx43, granulosa cells were treated with testosterone in the presence or absence of 0.1 μM 1,25D₃. We determined the cellular localization of Cx43 using immunofluorescence and observed its expression as green fluorescent plaques (Figure 5A). Cx43 protein expression was markedly decreased when cells were treated with a high dose of testosterone (1 μg/mL; p < 0.005), but this effect was reversed by pre-treatment with 1,25D₃ (p < 0.05; Figure 5A, B). We performed a real-time PCR analysis and found that cultured cells pre-treated with 1,25D₃ also reversed testosterone (1 μg/mL)-induced down-regulation of Cx43 (p < 0.05; Figure 5C). These results indicated that 1,25D₃ abolishes the inhibitory effect of testosterone on Cx43 expression in granulosa cells.

Discussion

Testosterone can induce concentration-dependent physiological and pathological effects. Physiologic levels of testosterone are converted into sufficient 17β-estradiol to improve follicular development, and the pathological
effects of testosterone may be due to induced hyperandrogenism and arrested follicular development. Androgen concentrations in the follicular fluid (FF) are higher in small follicles than in large follicles, and the androgen concentration in PCOS FF is higher than in FF from healthy women [30,31]. In the present study, we have demonstrated the dose dependence of testosterone-induced aromatase expression (Figure 1A) and 17β-estradiol secretion (Figures 1B and 3A). These results are consistent with a previous report demonstrating that testosterone increases aromatase mRNA levels [2]. Testosterone increases the levels of aromatase mRNA promoter 1.1- and 1.5-derived transcripts at 1 μM but only increases the promoter 2-derived transcript at the highest (100 μM) dose [9]. Interestingly, we found that 1,25D₃ reduced testosterone-induced aromatase expression but stimulated 17β-estradiol secretion (Figure 1A, B). 1,25D₃ appears to modulate aromatase expression in the estrogensis of granulosa cells and has been shown to exert tissue-specific effects on aromatase expression by various promoters [32]. For example, 1,25D₃ increases aromatase expression in placental cells and osteoblasts but down-regulates aromatase expression in breast cancer cells [33-35]. Lundqvist et al. also demonstrated that a 1,25D₃ analogue reduces aromatase expression by promoting dissociation of the co-modulator Williams syndrome transcription factor from the cyp19a1 promoter in breast cancer cells [36]. In addition, competition for shared coregulators between VDR and AR is one possible explanation for the suppressive effect of 1,25D₃/VDR signals on AR transcriptional activity [37]. In our study, we found that treatment with 1,25D₃ alone reduced aromatase expression but did not alter 17β-estradiol secretion (Figure 1A, C). Thus, 1,25D₃ exhibits a synergist effect in attenuating testosterone-induced aromatase expression.

Recently, aromatase activity was shown to mediate post-translational modifications. Changes in aromatase activity
often reflect differential protein expression arising from a slow rate of mRNA transcription. The phosphorylation of aromatase rapidly regulates estradiol production. For example, studies of murine aromatase suggest that serine 118 [38] or tyrosine 361 [20] can be phosphorylated and affect aromatase stability or activity. Specifically, increases in aromatase activity and estradiol secretion are regulated by c-Src kinase-catalysed tyrosine phosphorylation [20] and inhibits in aromatase activity by protein tyrosine phosphatase 1B in breast cancer cells [39]. Our study, although 1,25D3 inhibited aromatase protein expression, we also found that it can regulate tyrosine phosphorylation and change the activity of aromatase to improve 17β-estradiol secretion at longer times. We demonstrated that 1,25D3 treatment led to a significantly increased aromatase tyrosine phosphorylation level at 30 min, 6 h (Figure 2C) and 24 h (Figure 2A, left) compared with testosterone alone (Figure 2A, C). 1,25D3 also increased the level of aromatase tyrosine phosphorylation without testosterone at 24 h (Figure 2A, right). No difference in 17β-estradiol concentration between the testosterone and 1,25D3/testosterone groups was observed within the first 6 h (Figure 2D), but 1,25D3 markedly increased 17β-estradiol secretion at 18–24 h (Figure 2E). These results might suggest that a sustained, 1,25D3-induced increase in aromatase tyrosine phosphorylation maintains the effect of testosterone on 17β-estradiol secretion at 18–24 h. Thus, the 13% increase in 17β-estradiol production might arise at later times during the 24 h treatment with 1,25D3. Because VDRs are located in the largest follicles, the 13% increase in 17β-estradiol from 1,25D3/testosterone treatment might assist growth of the largest follicles. 1,25D3 might in this way inhibit aromatase expression and prevent aromatase excess syndrome, and increased aromatase tyrosine phosphorylation may rapidly regulate 17β-estradiol in the appropriate time frame.

1,25D3 is also known to promote calcium absorption from intestinal cells [40]; however, there was no clear evidence suggesting that 1,25D3 increased calcium accumulation in granulosa cells. Two different calcium channels (T-type and L-type) are involved in steroidogenesis in granulosa cells [41]. In this study, we observed that an L-type calcium channel blocker reduced 17β-estradiol secretion under 1,25D3/testosterone (0.01 or 1 μg/mL) treatment (Figure 3A). 1,25D3/testosterone-induced 17β-estradiol secretion was also significantly reduced by an intracellular calcium chelator. Additionally, NIF (10 μM) or BAPTA-AM (10 μM) alone did not cause cell toxicity (Figure 3C), and this dose of BAPTA-AM also reduces testosterone-induced 17β-estradiol secretion without 1,25D3 (Figure 3B). These results are similar to a report that implicated a calcium-dependent pathway in mediation of gonadotropin-induced steroidogenesis in the ovary [42]. Weitzel et al. demonstrated that calcium signals are critical in the inhibition of low-density lipoprotein receptor-1-mediated estradiol production in murine granulosa cells [43]. Our data is the first to illustrate that stimulation of 17β-estradiol production by 1,25D3 and testosterone is mediated by the L-type calcium channel and intracellular calcium levels (Figure 3).

Several effects of 17β-estradiol have been shown to be important for follicular development and ovarian function, including the regulation of ER levels, stimulation of DNA synthesis, cell proliferation and regulation of atresia in ovarian follicles [44]. ERβ is the important ER member expressed in growing granulosa cells and the mature follicle in rodent ovaries and is critical to granulosa cell proliferation and differentiation [45]. We have demonstrated that testosterone-treated granulosa cells exhibited significantly increased ERβ levels and that 1,25D3 did not alter testosterone-induced ERβ expression (Figure 4A). This result is similar to the finding that the expression levels of ERβ mRNA in the ovaries of VDR-null mutant and wild-type mice are the same [16]. Additionally, both testosterone and 1,25D3 had no effect on VDR expression (Figure 4B). These results might suggest that testosterone or 1,25D3/testosterone increases ERβ levels but not VDR levels.

Intercellular and intracellular endocrine regulatory mechanisms may be critical for follicle growth, dominant follicle selection, and follicle atresia. As ovarian follicles grow from the small to the large antral stage, granulosa cells provide 17β-estradiol by aromatase activation for dominant follicle development [46]. In contrast, other small follicles undergo atresia via apoptosis [47]. AR is expressed in primordial follicles, advanced-stage follicles and primary follicles [5], and testosterone stimulates the early stages of follicle growth, inhibits preovulatory follicle apoptosis and limits follicle size [6]. Thus, the observation that many small follicles grow in PCOS may be explained by excess testosterone. Alternatively, 1,25D3 might inhibit the testosterone-stimulated early stages of follicular growth because 1,25D3 is known to inhibit the proliferation and induce the differentiation of a variety of cells [48], and VDR is expressed in the granulosa cells of largest follicle [49]. It is possible that 1,25D3 paired with testosterone preferentially improves the growth of larger follicles. Hence, the effect of 1,25D3 and testosterone on aromatase in granulosa cells might indicate a plausible treatment option for PCOS. Several reports have also shown that 1,25D3 regulates antimüllerian hormone (AMH) signalling, follicle-stimulating hormone sensitivity, and progesterone production in human granulosa cells, and decreases the abnormally elevated AMH levels in 1,25D3-deficient women with PCOS, indicating a critical role for 1,25D3 in follicular development [50].

Intercellular communication via gap junctions is vitally important for granulosa cell differentiation and oocyte
growth [22]. In this study, western blot analysis, qRT-PCR and immunostaining showed that high dose (1 μg/mL) of testosterone decreased Cx43 protein expression in granulosa cells, and this decrease was reversed by co-treatment with 0.1 μM 1,25-D3 (Figure 5). These results are similar to the finding that excess DHT down-regulates Cx43 in granulosa cells [25]. The correlation between abnormal androgen concentrations and Cx43 expression might contribute to the pathogenesis of PCOS, and 1,25D3 might prevent Cx43 down-regulation.

Conclusions

We determined that testosterone treatment increased aromatase expression and increased 17β-estradiol secretion in granulosa cells. 1,25D3 decreased testosterone-induced aromatase expression but significantly increased aromatase phosphotyrosine levels and lengthened the duration of testosterone-induced 17β-estradiol secretion in rat granulosa cells to 18–24 h. We also determined that 1,25D3/testosterone-induced 17β-estradiol secretion is dependent on changes in calcium levels. Additionally, testosterone increased ERβ expression, but neither 1,25D3 nor testosterone mediated VDR expression. Finally, a high dose of testosterone reduced Cx43 expression, and 1,25D3 abolished testosterone-reduced Cx43 levels.

Abbreviations

AMH: Anti-Müllerian hormone; AR: Androgen receptors; BAPTA-AM: bis-(a-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl)ester; Cx43: Connexin 43; 1,25D3: 1,25-dihydroxyvitamin D3; DHT: Dihydrotestosterone; ERβ: Estradiol receptor β; FF: Follicular fluid; FSH: Follicle-stimulating hormone; NIH: Nifedipine; PCOS: Polycystic ovary syndrome; VDR: 1,25-dihydroxyvitamin D3 receptor.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CTL conceived and performed experiments, conducted statistical analysis and contributed to data interpretation. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Taiwan National Science Council Grant NSC 102-2629-B-038-001, Taipei Medical University of Taiwan (TMU98-AE1-B01), and Hsin Sheng College of Medical Care and Management of Taiwan (HSC-102-010). English language correction of this article has been accomplished by language editing services, ELSEVIER.

Author details

1Department of Nursing, Hsin Sheng College of Medical Care and Management, Taoyuan, Taiwan. 2Department of Neurology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 3General Education Center, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. 4Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Received: 8 May 2014 Accepted: 13 September 2014 Published: 20 September 2014

References

1. Ryan KJ: Biochemistry of aromatase: significance to female reproductive physiology. Cancer Res 1982, 42:3342–3344.
2. Luo W, Witthohn MC: Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells. Biol Reprod 2006, 75:217–225.
3. Belin F, Goudet G, Duchamp G, Gerard N: Intracellular concentrations of steroids and steroidoenzymes in relation to follicular development in the mare. Biol Reprod 2000, 62:1335–1343.
4. Stocco C: Aromatase expression in the ovary: hormonal and molecular regulation. Steroids 2008, 73:473–487.
5. Ota M, Makinen S, Tuuri T, Sjoberg J, Penttilainen M, Ylikahri T, Dunkel L: Effects of testosterone, dihydrotestosterone, and 17beta-estradiol on human ovarian tissue survival in culture. Fertil Steril 2004, 82(Suppl 3):1077–1085.
6. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA: Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998, 101:2622–2629.
7. Murray AA, Godsen RG, Allison V, Spears N: Effect of androgens on the development of mouse follicles growing in vitro. J Reprod Fertil 1998, 113:27–33.
8. Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu Q, Zhou X, Chao HT, Tsai MY, Chang C: Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci U S A 2004, 101:11209–11214.
9. Hamei M, Varselov J, Nicolaus ES, Price CA: Androstenedione increases cytochrome P450 aromatase messenger ribonucleic acid transcripts in nonluteinizing bovine granulosa cells. Mol Reprod Dev 2005, 70:175–183.
10. Wu Y, Bennett J, Talla D, Stocco C, Testosterone, not Salapha- dihydrotestosterone, stimulates LH-R1 leading to FSH-independent expression of Cyp19 and P450sc in granulosa cells. Mol Endocrinol 2011, 25:566–568.
11. Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS: Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertil Steril 2007, 88:727–729.
12. Wehr E, Pilt S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B: Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009, 161:575–582.
13. Wehr E, Trummer O, Gaulani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B: Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol 2011, 164:241–249.
14. Lerchbaum E, Obermayer-Pietsch B: Vitamin D and fertility: a systematic review. Eur J Endocrinol 2012, 166:765–778.
15. Johnson JA, Grande JP, Roche PC, Kumar R: Immunohistochemical detection and distribution of the 1,25-dihydroxyvitamin D3 receptor in rat reproductive tissues. Histochem Cell Biol 1996, 105:75–17.
16. Kinuta K, Tange A, Moriwake T, Aya K, Kato S, Seino Y: Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317–1324.
17. Boland R, Buitrago C, De Boland AR: Modulation of tyrosine phosphorylation signalling pathways by 1-alpha,25(OH(2))-vitamin D3. Trends Endocrinol Metab 2005, 16:280–287.
18. Buitrago C, Vazquez G, De Boland AR, Boland RL: Activation of Src kinase in skeletal muscle cells by 1, 1,25-(OH(2))-vitamin D3 correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) and VDR-Src interaction. J Cell Biochem 2000, 79:274–281.
19. Buitrago C, Vazquez G, De Boland AR, Boland R: The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH(2))D3. Biochem Biophys Res Commun 2001, 289:1150–1156.
20. Catalano S, Barone I, Giordano C, Raza F, Qi H, Gu G, Malividhi R, Bondofilia D, Ardo S: Rapid estradiol/ERalpha signaling enhances aromatase enzymatic activity in breast cancer cells. Mol Endocrinol 2009, 23:1634–1645.
21. Cheng J, Watkins SC, Walker WH: Testosterone activates mitogen-activated protein kinase via Src kinase and the epidermal growth factor receptor in sertoli cells. Endocrinology 2007, 148:2066–2074.
22. Kidder GM, Mhatre AA: Gap junctions and ovarian folliculogenesis. Reproduction 2002, 123:615–620.
23. Tellmann SC: Differential expression and localisation of connexin-37 and connexin-43 in follicles of different stages in the 4-week-old mouse ovary. Mol Cell Endocrinol 2005, 234:27–35.
24. Acket CL, Gittens JE, O’Brien MJ, Eppig JJ, Kidder GM: Intracellular communication via connexin43 gap junctions is required for ovarian folliculogenesis in the mouse. Dev Biol 2001, 233:258–270.
25. Wu CH, Yang JG, Yang JJ, Lin YM, Tsai HD, Lin CY, Kuo PL: Androgen excess down-regulates connexin43 in a human granulosa cell line. Fertil Steril 2010, 94:2938–2941.

26. Clairmont A, Tesman D, Stock A, Nicolai S, Stahl W, Sies H: Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts. J Endocrinol 2005, 184:555–566.

27. Ke FC, Fang SH, Lee MT, Sheu SY, Lai SY, Chen YJ, Huang FL, Wang PS, Stocco DM, Hwang JJ: Lindane, a gap junction blocker, suppresses SHF and transforming growth factor beta1-induced connexin43 gap junction formation and steroidogenesis in rat granulosa cells. J Endocrinol 2005, 184:555–566.

28. Mierhi Z, Doswell A, Krebs K, Cipolla M: Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. J Clin Endocrinol Metab 2014, 99:E1137–1145.

29. Morsmann T: Rapid colormetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55–63.

30. Teissier MP, Chabbe H, Paulhas S, Aubard Y: Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Hum Reprod 2003, 18:2471–2477.

31. Elisa Nielsen M, Rasmussen IA, Fukuda M, Westergaard LG, Yding Andersen C: Concentrations of anti-Mullerian hormone in fluid from small human antral follicles show a negative correlation with CYP19 mRNA expression in the corresponding granulosa cells. Mol Hum Reprod 2010, 16:637–643.

32. Lundqvist J, Noflin M,Wikvall K: 1,25-Dihydroxyvitamin D3 exerts tissue-specific effects on estrogen and androgen metabolism. Biochim Biophys Acta 1811, 2011,1623–270.

33. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D: Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 151:32–42.

34. Enjuanes A, Garcia-Giralt N, Supervia A, Nogues X, Ruiz-Gaspa S, Bustamante M, Mellbovsky L, Grinberg D, Balcells S, Diez-Perez A: Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. J Immunol Methods 2005, 153:981–988.

35. Barrera D, Avila E, Hernández G, Alalqui A, Binuet B, Lareea F, Díaz L: Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J Steroid Biochem Mol Biol 2007, 103:529–532.

36. Lundqvist J, Hansen SK, Lykkefeldt AE: Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter—a new regulatory pathway for aromatase. Biochim Biophys Acta 1833, 2013,40–47.

37. Ting HJ, Bao BY, Hsu CL, Lee YF: Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. Endocrine 2005, 26:3–9.

38. Miller TW, Shin I, Kagawa N, Evans DB, Waterman MR, Arteaga CL: Aromatase is phosphorylated in situ at serine-118. J Steroid Biochem Mol Biol 2008, 112:95–101.

39. Barone I, Giordano C, Malivindi R, Lanzino M, Rizza P, Casaburi I, Bonofiglio D, Catalano S, Ando S: Estrogens and PTP1B function in a novel pathway to regulate aromatase enzymatic activity in breast cancer cells. Endocrinology 2012, 153:5157–5166.

40. Christakos S, Dhawan P, Porta A, Mady LJ, Seth T: Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol 2011, 347:25–29.

41. Agoston A, Kurz L, Krieger A, Mayerhofer A: Two types of calcium channels in human ovarian endocrine cells: involvement in steroidogenesis. J Clin Endocrinol Metab 2004, 89:4503–4512.

42. Paul S, Kundu S, Pramanick K, Bandyopadhyay A, Mukherjee D: Regulation of ovarian steroidogenesis in vitro by gonadotropin in common carp Cyprinus carpio: interaction between calcium- and adenylate cyclase-dependent pathways and involvement of ERK signaling cascade. J Mol Endocrinol 2010, 45:207–218.

43. Weitzel JM, Vemunut A, Kruger B, Plinski C, Vergutz T: LOX-1 regulates estrogenogenesis via intracellular calcium release from bovine granulosa cells. Gynecol Obstet 2014, 85:88–93.

44. Reilly CM, Cannady WE, Mahesh VB, Stopper VS, De Sevilla JM, Mills TM: Duration of estrogen exposure prior to follicle-stimulating hormone stimulation is critical to granulosa cell growth and differentiation in rats. Biol Reprod 1996, 54:1336–1342.

45. Emmen JM, Couse JF, Elmore SA, Yates MM, Kissling GE, Korach KS: In vitro growth and ovulation of follicles from ovaries of estrogen receptor (ER) alpha and ER (beta) null mice indicate a role for ER (beta) in follicular maturation. Endocrinology 2005, 146:2817–2826.

46. Gougeon A: Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. Ann Endocrinol (Paris) 2010, 71:132–143.

47. Matsuda F, Inoue N, Manabe N, Ohkura S: Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev 2012, 58:44–50.

48. Kimura K: Regulation of vitamin D biosynthesis by calcium. Clin Calcium 2003, 13:899–903.

49. Wojtusik J, Johnson PA: Vitamin D regulates anti-Mullerian hormone expression in granulosa cells of the hen. Biol Reprod 2012, 86:91.

50. Iriti M, Mierhi Z: Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril 2014, 102:460–468 e463.